display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
breast cancer HER 2 negative
mBC - HER 2 negative
immune chekpoint inhibitors
anti-PD-(L)1
durvalumab based treatment
durvalumab alone Saphir02 Breast-Immuno

Study type:

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons